Status:
COMPLETED
Long-term Management of Patients With Ruptured HCC
Lead Sponsor:
University Hospital, Caen
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The main objective of this work is to evaluate the prevalence and results of specific management of HCC after spontaneous rupture, since the arrival of sorafenib in 2008.
Detailed Description
Retrospective, observational, multicenter study over the period from January 2008 to April 2024. Cases had to be 18 years or older. They were identified by two different methodologies adapted to the ...
Eligibility Criteria
Inclusion
- Ruptured hepatocellular carcinoma with or without cirrhosis
Exclusion
- Liver adenoma without histologically proven HCC
- Other benign or malignant liver tumors
- ATCD of potentially triggering interventional procedure in the previous month.
- Hemorrhagic ascites without tumor
- Intratumoral hemorrhages without hemoperitoneum or capsular rupture
Key Trial Info
Start Date :
January 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2024
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT06505291
Start Date
January 1 2008
End Date
April 30 2024
Last Update
July 17 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.